This study is in progress, not accepting new patients
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Summary
- Eligibility
- for people ages 12-65 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Longboard Pharmaceuticals
- ID
- NCT05626634
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 50 study participants
- Last Updated